Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. ADC Therapeutics's Revenue for the
three
months ended in Mar. 2026 was $20.85 Mil. ADC Therapeutics's average Accounts Receivable for the
three
months ended in Mar. 2026 was $30.08 Mil.
Hence, ADC Therapeutics's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.69.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
ADC Therapeutics Receivables Turnover Related Terms
ADC Therapeutics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for ADC Therapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADCT vs GNLX, VXRT, COYA: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ADC Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADC Therapeutics Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ADC Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where ADC Therapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADC Therapeutics (ADCT) has a Receivables Turnover of 0.69 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on ADC Therapeutics and its competitors. According to the industry distribution chart, ADC Therapeutics ranks #797 out of 948 companies in the Drug Manufacturers industry, placing it in the top 84.1%.
Is ADC Therapeutics' Receivables Turnover too high?
ADC Therapeutics' current Receivables Turnover is 0.69. The Drug Manufacturers industry median Receivables Turnover is 5.07. ADC Therapeutics' value of 0.69 is 86.4% below this industry median. Based on the distribution chart, ADC Therapeutics ranks #797 out of 948 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ADC Therapeutics has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ADC Therapeutics' Receivables Turnover compare to GNLX and VXRT?
According to the Drug Manufacturers industry distribution chart, ADC Therapeutics ranks #797 out of 948 companies for Receivables Turnover. This places ADC Therapeutics in the lower half of its industry. The industry median Receivables Turnover is 5.07. ADC Therapeutics' value of 0.69 is 86.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADC Therapeutics's current Receivables Turnover of 0.69 is 86.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on ADC Therapeutics and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADC Therapeutics's current Receivables Turnover is 0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADC Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, ADC Therapeutics (ADCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.09, compared to a current price of $1.26 — trading 39.7% below its estimated fair value. The current Receivables Turnover is 0.69 and 86.4% below the Drug Manufacturers industry median of 5.07. ADC Therapeutics' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For ADC Therapeutics (ADCT), the current Receivables Turnover is 0.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADC Therapeutics (ADCT) Overvalued in 2026?
Based on GuruFocus' analysis, ADC Therapeutics stock appears to be undervalued.
The current stock price of $1.26 is trading 39.7% below its estimated GF Value™ of $2.09.
GuruFocus considers ADC Therapeutics to be Possible Value Trap.
Key valuation signals for ADCT:
Receivables Turnover: 0.69
GF Value™: $2.09 vs. price of $1.26 (39.7% below fair value)
Industry Position: 86.4% below the Drug Manufacturers median (#797 of 948)
No single metric tells the full story. See the ADCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
41GF Score
Get the complete analysis for ADCT
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADCT has been successfully added to your 
